BIOCRYST PHARMACEUTICALS, INC. Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2026-05-06: Individual Ron Dullinger; Title Chief Commercial Officer; Arrangement Rule 10b5-1; Adopted March 2, 2026.
- 2026-05-06: Individual Jon Stonehouse; Title Member of the Board of Directors; Arrangement Rule 10b5-1; Adopted March 3, 2026.
- 2026-05-06: .
- 2026-05-06: .
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2026-05-06 10-Q | Ron Dullinger | Chief Commercial Officer | Rule 10b5-1 | March 2, 2026 | February 26, 2027 P139D | ||
| 2026-05-06 10-Q | Jon Stonehouse | Member of the Board of Directors | Rule 10b5-1 | March 3, 2026 | December 31, 2027 P668D | 800,000 | |
| 2026-05-06 10-Q | 151,868 | ||||||
| 2026-05-06 10-Q | 64,738 | ||||||
| 2025-11-04 10-Q | A. Machelle Sanders | Member of the Board of Directors | Rule 10b5-1 | August 14, 2025 | December 31, 2025 P139D | 9,600 | |
| 2024-08-06 10-Q | Nancy J. Hutson, Ph.D. | Director, Chair of the Board | Rule 10b5-1 | June 18, 2024 | P196D | 7,000 | |
| 2024-02-27 10-K | Jon P. Stonehouse | President and Chief Executive Officer | Rule 10b5-1 | November 7, 2023 | |||
| 2024-02-27 10-K | Anthony J. Doyle | Chief Financial Officer and Treasurer | Rule 10b5-1 | November 7, 2023 | |||
| 2024-02-27 10-K | Helen M. Thackray, M.D. | Chief Research & Development Officer | Rule 10b5-1 | November 8, 2023 | |||
| 2024-02-27 10-K | Alane P. Barnes | Chief Legal Officer and Secretary | Rule 10b5-1 | November 7, 2023 | |||
| 2024-02-27 10-K | Charles K. Gayer | Chief Commercial Officer | Rule 10b5-1 | November 7, 2023 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |